Showing 2271-2280 of 3223 results for "".
- Allergan Lifts Earnings Target, Says No Drug Price Hikes This Yearhttps://modernod.com/news/allergan-lifts-earnings-target-says-no-drug-price-hikes-this-year/2479979/Allergan raised its yearly earnings forecast on Thursday thanks to rising sales of mainstay product Botox, and said it did not expect to increase drug prices this year, according to a
- Alcon Unveils Next-Generation Forceps to Improve Precision and Reduce Trauma During Retina Surgeryhttps://modernod.com/news/alcon-unveils-next-generation-forceps-to-improve-precision-and-reduce-trauma-during-retina-surgery/2479998/Alcon has launched the new Finesse Sharkskin ILM Forceps at the the American Society of Retina Specialists (ASRS) meeting. The next-generation tool is designed to provide increased surgical precision and to enhance retina surgery outcomes. The new forceps have a large grasping platform and a text
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a
- Alcon Introduces Ngenuity 3D Visualization System with Datafusion Vitreoretinal Surgery Devicehttps://modernod.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/Alcon launched the new Ngenuity 3D Visualization System with Datafusion at the 2018 American Society of Retina Specialists (ASRS) annual meeting. With the addition of the Datafusion software, Ngenuity now also offers integration with the Constellation Vision System for vitreoretinal surgery. The
- Allergan and Molecular Partners Announce Positive Phase 3 Clinical Trials for Abicipar Pegol for the Treatment of Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-positive-phase-3-clinical-trials-for-abicipar-pegol-for-the-treatment-of-wet-amd/2480008/Allergan and Molecular Partners announced the release of two positive clinical trials, SEQUOIA and CEDAR, for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the prespecified primary endpoint of noninferiority to ranibizumab. SEQUOIA and CEDAR are identical
- Allergan Launches New Refresh Repair Lubricant Eye Dropshttps://modernod.com/news/allergan-launches-new-refresh-repair-lubricant-eye-drops/2480034/Allergan announced the launch of a new over-the-counter artificial tear formulation, Refresh Repair Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants, Refresh Repair
- Oculocare’s Alleye Receives FDA 510(k) Clearance for Monitoring Eyesight in AMDhttps://modernod.com/news/oculocares-alleye-receives-fda-510k-clearance-for-monitoring-eyesight-in-amd/2480036/Oculocare Medical announced the FDA 510(k) clearance of Alleye, a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD). Alleye is designed to detect and characterize central and paracentral metamorphopsia (visual distortio
- Elsalys Biotech: New Studies Confirm Anti-CD160 Potential in Ophthalmologyhttps://modernod.com/news/elsalys-biotech-new-studies-confirm-anti-cd160-potential-in-ophthalmology/2480045/Elsalys Biotech, announced the publication of two studies validating the potential of its first-in-class anti-CD160 antibodies for the treatment of neovascular diseases of the eye. The first study reveals that in patients, CD160 endothelial expression in ret
- Novartis Chairman Says Alcon Worth $20 Billion to $30 Billion: Finanz und Wirtschafthttps://modernod.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/The chairman of Swiss Novartis expects Alcon to be valued at between $20 billion and $30 billion when the ophthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft, according to a Reuters
- Novartis Announces Intention to Spinoff Alcon Into Standalone Companyhttps://modernod.com/news/novartis-announces-intention-to-spinoff-alcon-and-launch-a-5-billion-share-buyback/2480055/After months of speculation, Novartis confirmed on Friday its intention to spinoff Alcon into a separately-traded standalone company. The major transaction would enable Novartis to focus on bringing new drugs to market, while allowing Alcon to focus on its core offerings in the surgical and visio